

- 7 -

WE CLAIM

1. A therapeutic composition, comprising a non-toxic transglutaminase inhibitor having a free amino group or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable carrier or diluent.

2. A composition according to claim 1, wherein the inhibitor is a primary amine.

3. A composition according to claim 2, wherein the amine is a polyamine. *a*

4. A composition according to claim 3, wherein the amine is aliphatic.

5. A composition according to claim 4, wherein the amine is a C1-5 alkyl amine.

6. A composition according to claim 5, wherein the amine is putrescine.

7. A composition according to claim 6, wherein the carrier is a eutectic cream or ointment.

*Sub B1*  
8. A method of treating hypertrophic scar tissue, comprising applying to the scar tissue an effective amount of a non-toxic transglutaminase inhibitor having a free amino group or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable carrier or diluent.

*2-9*  
9. A method according to claim 8, wherein the effective amount is 25 to 100 mM.

*3-10*  
10. A method according to claim *9*, wherein the effective amount is about 50 mM.

*Sub B2*  
11. A method according to claim *10*, wherein the inhibitor is a

*9*  
**SUBSTITUTE SHEET**

- 8 -

*Delc*  
*B2*  
primary amine.*5* 12. A method according to claim *4*, wherein the amine is a polyamine.*6* 13. A method according to claim *5* 12, wherein the amine is a C1-5 alkyl amine.*7* 14. A method according to claim *10* 13, wherein the amine is putrescine.*8* 15. A method according to claim *7* 14, wherein the carrier is a eutectic cream or ointment.*Add*  
*B3**Ph 10*  
SUBSTITUTE SHEET